10-year results of a phase 3 RCT: High-dose radiotherapy and risk-adapted androgen deprivation in localized prostate cancer.
19 Apr, 2022 | 01:22h | UTCHigh-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial – The Lancet Oncology (link to abstract – $ for full-text)